Topical dipeptide (alanyl-glutamine)

Class

Topical dipeptide (alanyl-glutamine) — anti-protein-carbamylation agent

Pathway

Inhibition of carbamylation of skin amino acids/proteins by urea-derived cyanate — CKD-associated pruritus (no discrete receptor target; MC2 Therapeutics' PAD Cream Technology topical platform)

Notes

original target text: Topical dipeptide (alanyl-glutamine) — anti-protein-carbamylation agent

This mechanism does not involve a classical receptor or enzyme target but instead addresses a chemical process called protein carbamylation. In chronic kidney disease, impaired clearance of urea allows it to break down into cyanate, a reactive small molecule that can attach to lysine residues on proteins, altering their structure and function. In skin, this carbamylation has been proposed to contribute to persistent itching (pruritus), a common and difficult-to-treat symptom in people with advanced kidney disease. The topical dipeptide alanyl-glutamine is designed to intercept cyanate before it can react with skin proteins, acting as a competing reactive partner that is applied directly to the affected tissue. This approach targets a downstream chemical consequence of uremia locally, at the skin, rather than modulating a signaling receptor or correcting the underlying renal dysfunction. The rationale for a topical, localized strategy is that it can address a bothersome symptom without requiring systemic drug exposure or altering kidney urea handling itself. Because the target is a chemical reaction rather than a protein binding site, the intervention broadly matters wherever carbamylation-driven tissue changes contribute to symptoms, with chronic kidney disease-associated pruritus being the principal example discussed here.